A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals

Venous thromboembolism (VTE) is a life-threatening disorder and a major cause of morbidities and mortality among hospitalized patients [1]. The condition is characterized by the development of thrombosis of deep veins of the leg or pelvis (DVT) that propagate to the pulmonary circulation leading to pulmonary embolism (PE) [2]. According to previous epidemiological studies, VTE is the third most common cardiovascular disease with reported incidence rates of 130 and 100 per 100,000 persons every year for men and women, respectively [3]. Old age, obesity, prolonged immobility, acute heart failure, malignancy, hyperestrogenemia, and genetic susceptibility are major risk factors for VTE development [4]. Hospitalized patients are at increased risks of VTE due to the presence of multiple risk factors that are usually cumulative [5]. Despite that VTE has been previously described as a complication of major surgery, recently published evidence shows that hospitalized patients with a medical illness have comparable risks of VTE to that of the patients undergoing major surgery [6]. Previous reports demonstrated that up to 20% of hospitalized medical patients are expected to develop VTE during hospital stay [7]. VTE is a major cause of mortality in hospitalized patients as well; up to 10% of fatality cases during hospitalization were attributed to VTE in autopsy-based studies [8]. Therefore, effective VTE prophylaxis among hospitalized at-risk patients, either surgical or medical, is critical in improving patients’ outcomes and survival [9].

Anticoagulants represent the cornerstone for VTE prophylaxis among hospitalized patients [10]. Historically, unfractionated heparin (UFH) was the anticoagulant of choice for VTE prophylaxis; however, the current body of evidence shows that low molecular weight heparin (LMWH) has a comparable efficacy profile, with more favorable safety data than UFH [11]. The American College of Chest Physicians (ACCP 2012) guidelines recommend using prophylactic anticoagulants in cases with a high risk of VTE [12]. They recommend using parenteral LMWH or fondaparinux as a first choice for VTE prophylaxis over IV UFH in the cases of acute deep venous thrombosis (DVT) or pulmonary embolism (PE). They also recommend using thrombolytic therapy in case of PE with hypotension. The guidelines also stated that, in cases of surgically provoked PE or DVT, 3 months of anticoagulant therapy is recommended. Also in the case of PE or DVT that is associated with active cancer, they recommend using LMWH therapy over vitamin K antagonist (warfarin). For extensive superficial vein thrombosis, they recommend a prophylactic therapy with fondaparinux or LMWH instead of no anticoagulants use, and they recommend fondaparinux over LMWH. Other treatment options as compression stockings were recommended to prevent post-thrombotic syndrome. Therefore, LMWH and fondaparinux are currently the first-line prophylaxis options in hospitalized patients [13]. Although multiple international guidelines recommend the use of VTE prophylaxis for at-risk hospitalized patients, the rates of prophylaxis strategies implementation are not satisfied in many regions [9]. The ENDORSE study reported that less than 40% of hospitalized medical patients receiving appropriate prophylaxis, with great variations in prophylaxis use between countries, regions, and hospitals [7].

The burden of VTE is presumably high among hospitalized patients from the Middle East region [14], as many countries from the region are listed among the top ten countries with the highest rate of non-communicable diseases, such as obesity, hypertension, and diabetes [15, 16]. In the AVAIL ME study [14], the rate of patients at a very high-risk for VTE was 40.9% in Iran, 32.7% in Jordan, 27.7% in Saudi Arabia, and 30,7 in Lebanon compared to only 16.7% in Azerbaijan. In the united states of America (USA), VTE is considered a major health problem as nearly 2 million new cases are reported every year with over 600,000 deaths from PE [17]. According to recent reports, the overall compliance with international guidelines concerning VTE prophylaxis was nearly 38% in the Middle Eastern countries, with wide geographical disparity [14]. In comparison to the countries included in the ENDORSE study [7]; the compliance to VTE prophylaxis guidelines was 68% in the USA, 54% in India, 55% in Kuwait, 81% in Germany, 60% in France, 34% in Egypt, 50% in Algeria, and 31% in Argentina [18]. However, the data on the degree of compliance with the current antithrombotic guidelines in the Middle East region is still scarce [19, 20]. Therefore, in this study, we aimed to assess the current practices of VTE prophylaxis among hospitalized patients in Jordan and Lebanon.

We followed the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology Statement) guidelines (Supplementary file no.1) during the preparation of this manuscript [21]. The present study runs in concordance with the principles of the declaration of Helsinki and applicable local regulatory laws. Written informed consent was obtained from every eligible patient, or their relatives, prior to the study’s enrollment.

The present study screened 705 patients from 40 sites across Lebanon and Jordan. Of them, 704 patients (400 from Jordan and 304 from Lebanon) (99.9%) were eligible for final analysis and one patient (0.1%) was excluded as the weight was above 100 kg. Regarding the demographic characteristics of the included patients, the patients’ age ranged from 18 to 93 years with a mean age of 54.9 ± 17.5 years. Almost 48% of the patients were males. The mean weight and height of the included patients were 75.7 ± 13.4 kg and 165.9 ± 9.3 cm, respectively. The BMI of the included patients ranged from 16.1 to 44.2 kg/m² with a mean BMI of 27.5 ± 4.8 kg/m². In terms of vital signs, the mean SBP and DBP of the included patients were 124.1 ± 15.4 and 73.8 ± 9.7 mmHg, respectively. Sixty percent of the patients had one or more current medical conditions. The most commonly encountered medical condition was hypertension (34.8%), followed by diabetes mellitus (22.6%) and coronary artery disease (10.1%). Two-hundred and forty-six (34.9%) patients were admitted for medical causes only, 449 (63.8%) patients were admitted for surgical causes only, and 9 (1.3%) patients were admitted for both medical and surgical causes. The average hospital stay of the included patients was 5.8 ± 8.4 days. The Demographic and clinical characteristics of the included patients were summarized in Table 1.

Six hundred and sixteen patients (87.5%) had one or more risk factors for VTE which were either surgical (55.5%), medical (31.4%), or surgical and medical risk factors (0.6%). Sixty patients (8.5%) had risk factors associated with increased bleeding such as active bleeding (1.1%) and low platelet count. In addition, 25 (3.5%) patients had risk factors associated with mechanical prophylaxis which were severe peripheral arterial disease (0.4%), congestive heart failure (2.8%), and acute superficial/deep vein thrombosis (0.3%).

Among the 704 patients who were eligible for the final analysis, 415 (58.9%) patients received prophylaxis treatment in form of pharmacological anticoagulant prophylaxis (n = 371, 52.7%), mechanical prophylaxis (n = 13, 1.8%), and pharmacological plus mechanical prophylaxis (n = 31, 4.4%). LMWH was the most commonly used anticoagulant for VTE prophylaxis (n = 366); however, the unfractionated heparin was administrated in 56 patients only as seen in Table 2. In Lebanon as well as Jordan, LMWH was the most commonly used anticoagulant for VTE prophylaxis (N = 192, 48%) and (N = 174, 57.2%), respectively (Table 3).

Among the total 704 eligible patients, 415 (58.9%) patients received VTE prophylaxis, while 289 (41.1%) did not receive prophylaxis. For those who received VTE prophylactic treatment, 216 (52, 95% CI [47.1–56.9%) received appropriate prophylactic agents according to ACCP guidelines. For those who were not treated with prophylactic agents, 212 (73.4, 95% CI [67.9–78.4%) were eligible for VTE prophylaxis according to ACCP guidelines as presented in Table 4.

About 60.9% (95% CI 51.9–69.4%) of the patients (n = 78) received VTE prophylaxis out of the medical patients who were eligible for prophylaxis according to ACCP 2016 guideline (n = 128). While in surgical patients, only 45.1% (95% CI 39.3–51%) of the patients (n = 133) received VTE prophylaxis out of those who were eligible for prophylaxis (n = 295), Fig. 1. All patients with combined medical and surgical conditions received appropriate prophylaxis.

Regarding the orthopedic surgery, most of the patients received appropriate VTE prophylaxis according to ACCP 2016 guideline. While in non-orthopedic surgery, the number of patients who received appropriate VTE prophylaxis (N = 170) was lower than the number of patients who were eligible for prophylaxis (N = 227) as seen in Fig. 2.

The supplementary file no.2 shows the distribution of appropriate VTE prophylaxis according to doctors’ specialty and the type of surgery.

Overall, the rate of compliance to ACCP guidelines was higher in private hospitals than in public hospitals (85% versus 57.8%, respectively). The rate of compliance to ACCP guidelines was higher among oncologists (73.3%) and general family specialists (72%) than other specialized doctors. The rate of compliance was higher among cases of orthopedic surgeries (100%) and oncological surgeries (79%) than other types of surgery as presented in Table 5.

The multivariate logistic regression analysis showed that only age was a significant predictor of appropriate VTE prophylaxis in the present study (OR 1.05, 95% CI [1.04–1.07], P < 0.001) (Table 6).

There is a growing body of evidence that shows substantial underuse of VTE prophylaxis in patients at risk [7]. However, the extent of VTE prophylaxis underuse in the Middle East is unclear. In the present observational, multinational, study, we found that the rates of the appropriate use of VTE prophylaxis were 60.93 and 45.08% of the medical and surgical hospitalized patients, who were eligible for VTE prophylaxis, respectively. Notably, there were wide variations in the rates of the appropriate use of VTE prophylaxis according to the type of hospitals, geographical areas, and the specialty of treating physicians. Finally, in the present study, we observed that the rate of an appropriate VTE prophylaxis according to the ACCP guidelines was increasing with the age of the patients: patients with old age (≥ 40 years) were associated with a higher rate of compliance to ACCP guidelines than young patients (< 40 years) [47.4% versus 20.5%]. In addition, the multivariate logistic regression analysis showed that only age was a significant predictor of appropriate VTE prophylaxis in the present study (OR 1.05, 95% CI [1.042–1.07], P < 0.001).

In 2017, Levine and colleagues showed that increasing age (OR 0.97, P < 0.001) of patients and a primary cardiovascular diagnosis (OR 0.18, P < 0.001) (chest pain, congestive heart failure, syncope/near-syncope, chronic ischemic heart disease, sinus tachycardia) decreased the likelihood of VTE prophylaxis [24].

The risk of VTE is a 10-fold higher in patients who are hospitalized after trauma, surgery, immobilizing medical illness, or pregnant and puerperal women than the general population. Accordingly, recent clinical guidelines strongly recommend the provision of pharmacological VTE prophylaxis in acutely or critically ill inpatients at risk [23, 25]. However, the present study showed that there is substantial underuse of VTE prophylaxis among hospitalized patients in Lebanon and Jordan; less than two-thirds of eligible medical patients received appropriate prophylaxis, while this rate was even much lower in surgical patients. The rate of appropriate VTE prophylaxis varied across different hospitals, geographical areas, and specialties; while the rate of compliance to ACCP guidelines was as low as 26% in some hospitals. These findings reflect the lack of standardized protocols for VTE prophylaxis use for hospitalized patients in both countries. Another possible explanation is the wide difference in the nature of participating hospitals; some of them had rural clinics and some of them were university/teaching hospitals. In accordance with our findings, a multicenter study from Lebanon in hospitalized patients reported that the rate of appropriate VTE prophylaxis was 65% of patients at low risk, 30% of patients at moderate risk, and 61% of patients at high risk [19]. A more recent report from Jordan reported that the rate of appropriate VTE prophylaxis was 67% in patients admitted to Jordan University Hospital; the study also demonstrated low compliance with the institutional guideline [26]. Other reports showed low rates of appropriate VTE prophylaxis use and guidelines compliance in Saudi Arabia [27] and Iran [28]. The AVAIL ME study reported that the overall rate of VTE prophylaxis use in the Middle East among eligible patients was 47.8% for medical patients and 60% for surgical patients; while the rate of compliance to ACCP guidelines was only 36% [22]. Globally, the multinational multicenter IMPROVE study reported that the appropriate use of VTE prophylaxis in eligible medical patients was 60% [29].

Although the underutilization of VTE prophylaxis in at-risk patients represents a major cause of in-hospital mortality and morbidity, inappropriate use of VTE prophylaxis in low-risk patients, when not medically indicated, can have a negative impact on patients’ outcomes leading to bleeding and drugs interaction [30]. In the present study, we found that 77.97% of the medical patients, who were not eligible for VTE prophylaxis, received prophylactic agents, compared to 66.88% of the surgical patients who were not eligible for VTE prophylaxis. Similar to our findings, a multicenter study from the United States (US) reported that 77.9% of hospitalized patients received excessive VTE prophylaxis without appropriate indication [31]. Another retrospective cohort study reported that pharmacological VTE prophylaxis was present in 74% of low-risk patients, who were not eligible for prophylaxis [30].